Clinical Trial Update: Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS [Phase 3]

View source ↗

Summary

Extension Phase 3 study evaluating the safety of oral edaravone in subjects with amyotrophic lateral sclerosis. Results were posted on 2025-02-03.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Edaravone (Edaravone)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: ALS | Phase 3 | Status: COMPLETED | Results posted: 2025-02-03